Prosecution Insights
Last updated: April 19, 2026
Application No. 17/584,811

PROCESS FOR DRYING A SUSPENSION AT ROOM TEMPERATURE

Final Rejection §103
Filed
Jan 26, 2022
Examiner
LEBLANC, KATHERINE DEGUIRE
Art Unit
1791
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Firmenich SA
OA Round
6 (Final)
34%
Grant Probability
At Risk
7-8
OA Rounds
4y 0m
To Grant
69%
With Interview

Examiner Intelligence

Grants only 34% of cases
34%
Career Allow Rate
201 granted / 596 resolved
-31.3% vs TC avg
Strong +35% interview lift
Without
With
+35.1%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
50 currently pending
Career history
646
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
57.1%
+17.1% vs TC avg
§102
9.1%
-30.9% vs TC avg
§112
28.0%
-12.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 596 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 17-22,24-29,31,32, 37-40 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bouquerand(US 2008/0206325). Regarding claims 17,18,19,27,28,31, Bouquerand teaches a non-spherical flavoring powdered microcapsule, comprising: (i)an oil phase comprising a volatile active ingredient(paragraph 27,28) ii) a water phase including a water-soluble carbohydrate carrier in the form of ocentyl-succinated starch(paragraph 70) (iii)an emulsifier(paragraph 89) (iv)a desiccant in the form of maltodextrin(paragraph 65) Bouquerand teaches that the particle can have a number of shapes including rod-like, disk-like, or flat(paragraph 22) which are generally not round and would be expected to have a low coefficient of circularity of less than 0.6. Furthermore, it would have been obvious to adjust the shape of the particle depending on the intended use of the final product. Bouquerand teaches that the particle can be a microcapsule(paragraph 34) in powdered form(paragraph 98) that is free flowing(paragraph 106). Bouquerand teaches that the particle has a water content of about 4% and an oil content of 30%(table 1, example 1A). This equates to a weight ratio of oil phase to water of 7.5. Bouquerand teaches that the volatile oil can be in the form of fish oil which inherently provides a flavor, i.e. is a flavoring microcapsule. Bouquerand further teaches the use of flavoring components at an amount of less than 30 wt%(paragraph 28). It would have been obvious to use a volatile flavor oil since flavor oils such as orange oil are commonly included in encapsulated products to provide a desired organoleptic effect. Regarding the limitation that the “the volatile active ingredient comprises a perfume or flavor oil suitable to impart a desired organoleptic effect”, Bouquerand teaches that the encapsulation of the fish oil prevents an undesirable flavor, therefore the encapsulated fish oil has a “desired organoleptic effect”, i.e. prevention of an undesirable flavor(paragraph 18). Furthermore, Bouquerand teaches that the composition can further include flavor components(paragraph 28) in order to cover up the unwanted taste of the fish oil. The flavor component(e.g. volatile flavor oil as stated above) therefore provides a desired organoleptic effect of masking the unpleasant taste of fish oil. Bouquerand teaches that the oil is freely dispersed in the water phase before the final drying phase to form the powder particles(paragraph 103, oil droplets do not coalesce in the water phase). Specifically, Bouquerand teaches forming an emulsion by mixing of a gelatin, gum Arabic, and water(water phase) with fish oil such that the oil droplets do not coalesce in water([0103]). Based on this description, it appears that all the oil droplets are freely dispersed in water. Furthermore, it is noted, that the limitation stating that the “oil is freely dispersed in the water phase” pertains to the method of making(oil can only be freely dispersed in the water phase in a liquid product before drying to form the final powder) and does not directly recite any clear structure to the final product. “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process”, In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Further, “although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an unobvious difference between the claimed product and the prior art product”, In re Marosi, 710 F.2d 798, 802, 218 USPQ 289, 292 (Fed. Cir.1983). See MPEP 2113. Therefore, absent evidence of criticality regarding the presently claimed process and given that Bouquerand meets the requirements of the claimed non-spherical flavoring powdered microcapsule, Bouquerand clearly meets the requirements of the present claims. Bouquerand teaches that the particles can have a range of mean particles sizes from 20µm to 2200 µm(table 1) depending on the method of production. Bouquerand teaches an average particle size of 400 microns(example 6). One of ordinary skill in the art would expect an average particle size of 400 microns to have some particles above and below the average size. For example, a size of 500 microns as expected with a typical particle size distribution. With particle sizes of 300-500 microns(average size of 400 microns), the composition would contain a fraction of particles of less than 500 microns, and a fraction of 500-800 microns as claimed. Furthermore, as particle size can be controlled via known methods in the art, it would have obvious to adjust the particle size depending on the nature of the encapsulated flavor. Regarding claim 20, Bouquerand does not specifically teach wherein the powder composition has part of said oil freely dispersed in the water phase and another part of the oil is dispersed in an encapsulated form in the water phase. However, Bouquerand teaches using similar materials(flavor oils, water soluble carbohydrates) processed in similar fashion to the claimed invention(simple or complex coacervation(paragraph 42)). Therefore, one of ordinary skill in the art would expect the powdered composition of Bouquerand to have the same properties as the claimed invention. Regarding claim 21, Bouquerand teaches that the encapsulated flavor oil is formed by simple or complex coacervation(paragraph 42). Regarding claim 22, Bouquerand teaches that the flavor oil is dispersed in an encapsulated form in the water phase(paragraph 103, oil droplets encapsulated in gum Arabic and gelatin are dispersed in the water phase). Regarding claim 24, Bouquerand teaches that the water-soluble carbohydrate carrier comprises ocentyl-succinated starch which is an emulsifying polymer with a molecular weight of 902 Daltons(paragraph 70). Regarding claim 25, Bouquerand teaches that the composition can comprise maltodextrin with a DE of from 15 to 19 which is water-soluble starch hydrolysate with a molecular weight lower than 1500 Dalton(paragraph 65). Regarding claim 26, Bouquerand teaches that the emulsifier can comprise gum Arabic(paragraph 39). Regarding claim 29, Bouquerand teaches that the powdered microcapsule can comprise a flowing agent such as silicon dioxide(paragraph 108). Regarding claim 32, Bouquerand does not specifically teach that method of forming the powdered composition as claimed. However, it is noted that “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process”, In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Further, “although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an unobvious difference between the claimed product and the prior art product”, In re Marosi, 710 F.2d 798, 802, 218 USPQ 289, 292 (Fed. Cir.1983). See MPEP 2113. Therefore, absent evidence of criticality regarding the presently claimed process and given that Bouquerand meets the requirements of the claimed non-spherical flavoring powdered microcapsule, Bouquerand clearly meets the requirements of the present claims. Regarding claim 37, Bouquerand teaches that the particles can have a range of mean particles sizes from 20µm to 2200 µm(table 1) depending on the method of production. As particle size can be controlled via known methods in the art, it would have obvious to adjust the particle size and amount of each fraction depending on the nature of the encapsulated flavor. Regarding claim 39, Bouquerand teaches that the powdered microcapsule is a coacervated microcapsule(para 21). Regarding claim 39 and 40, Bouquerand teaches that the particles can have a range of mean particles sizes from 20µm to 2200 µm(table 1) depending on the method of production. Bouquerand teaches an average particle size of 400 microns(example 6). One of ordinary skill in the art would expect an average particle size of 400 microns to have some particles above and below the average size. For example, a size of 500 microns as expected with a typical particle size distribution. With particle sizes of 300-500 microns(average size of 400 microns), the composition would contain a fraction of particles of less than 500 microns, and a fraction of 500-800 microns as claimed. Each fraction would have a different mesh size since each fraction has a different size range. Furthermore, as particle size can be controlled via known methods in the art, it would have obvious to adjust the particle size depending on the nature of the encapsulated flavor. Therefore, each fraction would “exclude larger particle sizes” as it only has particle sizes in the intended size range. Response to Arguments Applicant's arguments filed 7/10/2025 have been fully considered but they are not persuasive. The applicant argues that Bouquerand teaches away from large particles of 500-800 microns(see para 52). However, Bouquerand further teaches a free flowing powder with a larger average particle size range of 400 microns(example 6). Therefore, it is apparent that a larger particle size of 400 microns and produces a functional product, even if Bouquerand prefers a lower particle size. The applicant argues that a particle size of 500-800 microns provides unexpected results in terms of high flavor load of 25%. However, Bouquerand already teaches an even higher flavor load of 35%(see table 1, example 6). Furthermore, the present claims do not require two separate fractions, as in fractions that are not mixed together. The broadest, reasonable interpretation of the term “two distinct fractions” is that the composition has particle sizes from 500 to 800 microns and also particle sizes either lower than 500 microns and/or higher than 800 microns. As such, the claimed composition comprises a mixing of particle sizes and does not require the fractions to be separate. Bouquerand teaches that the particles can have a range of mean particles sizes from 20µm to 2200 µm(table 1) depending on the method of production. Bouquerand teaches an average particle size of 400 microns(example 6). One of ordinary skill in the art would expect an average particle size of 400 microns to have some particles above and below the average size. For example, a size of 500 microns as expected with a typical particle size distribution. With particle sizes of 300-500 microns(average size of 400 microns), the composition would contain a fraction of particles of less than 500 microns, and a fraction of 500-800 microns as claimed. Furthermore, as particle size can be controlled via known methods in the art, it would have obvious to adjust the particle size depending on the nature of the encapsulated flavor. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D LEBLANC whose telephone number is (571)270-1136. The examiner can normally be reached 8AM-4PM EST M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Nikki Dees can be reached at 571-270-3435. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D LEBLANC/ Primary Examiner, Art Unit 1791
Read full office action

Prosecution Timeline

Jan 26, 2022
Application Filed
Mar 09, 2024
Non-Final Rejection — §103
Jun 13, 2024
Response Filed
Aug 06, 2024
Final Rejection — §103
Sep 30, 2024
Response after Non-Final Action
Oct 24, 2024
Request for Continued Examination
Oct 25, 2024
Response after Non-Final Action
Nov 01, 2024
Non-Final Rejection — §103
Feb 06, 2025
Response Filed
May 14, 2025
Final Rejection — §103
Jul 02, 2025
Response after Non-Final Action
Jul 10, 2025
Request for Continued Examination
Jul 15, 2025
Response after Non-Final Action
Aug 07, 2025
Non-Final Rejection — §103
Nov 10, 2025
Response Filed
Nov 10, 2025
Applicant Interview (Telephonic)
Nov 29, 2025
Examiner Interview Summary
Mar 10, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600802
CONVERTED STARCH AND FOOD COMPRISING SAID CONVERTED STARCH
2y 5m to grant Granted Apr 14, 2026
Patent 12593859
HIGH LOAD FLAVOR PARTICLES
2y 5m to grant Granted Apr 07, 2026
Patent 12532897
FROZEN CONFECTION MANUFACTURE
2y 5m to grant Granted Jan 27, 2026
Patent 12495822
Structuring Agent for Use in Foods
2y 5m to grant Granted Dec 16, 2025
Patent 12478076
COFFEE COMPOSITION AND ITEMS MADE THEREFROM
2y 5m to grant Granted Nov 25, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
34%
Grant Probability
69%
With Interview (+35.1%)
4y 0m
Median Time to Grant
High
PTA Risk
Based on 596 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month